TPF induction
Checked 2026-09-09
Locally advanced head and neck cancer where induction is chosen (larynx preservation, bulky nodes)
One cycle
every 21 days × 3-4 · about 9 weeks in totalComponents
| Drug | Dose | Route | Days | Note |
|---|---|---|---|---|
Docetaxel Cytotoxic chemotherapy (taxane) | 75 mg/m² | IV | D1 | |
Cisplatin Cytotoxic chemotherapy (platinum) | 75 mg/m² | IV | D1 | |
Fluorouracil infusion Fluoropyrimidine antimetabolite | 750 mg/m² per day | IV | D1-5 (120 h infusion) |
Cycles
3-4, then chemoradiation
21-day cycle
Emetogenicity
High (>90%)
G-CSF
Recommended
Notes
- Antibiotic prophylaxis and G-CSF were required in TAX 324; treatment-related deaths limit use to fit patients.
Used in
Source
TAX 323 (EORTC 24971), NEJM 2007
Reference doses for a typical adult from the cited protocol or label. Doses are adjusted for renal and hepatic function, age, performance status and prior toxicity, and institutional protocols vary. Verify against the current label and your local protocol before treating. Not medical advice.
Other regimens for these cancers
Weekly cisplatin chemoradiation (with pembrolizumab for high-risk disease)
Locally advanced cervical cancer (FIGO IB2-IVA); pembrolizumab for FIGO 2014 III-IVA or node-positive
weekly × 5-6
Pembrolizumab monotherapy
Adjuvant melanoma stage IIB-IV (1 year); PD-L1 TPS 50% or above NSCLC; MSI-high tumours; recurrent head and neck (CPS 1 or above)
every 21 days
High-dose cisplatin chemoradiation
Locally advanced head and neck squamous cell carcinoma, definitive or postoperative (positive margins or extranodal extension)
every 21 days × 3
Pembrolizumab + platinum + fluorouracil
Recurrent or metastatic head and neck squamous cell carcinoma, first line
every 21 days